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Abstract
Background: Protein energy wasting (PEW) is common in patients undergoing maintenance hemodialysis (MHD)
and closely associated with poor outcomes. Insulin resistance and associated alterations in amino acid metabolism
are potential pathways leading to PEW. We hypothesized that the measurement of leucine disposal during a
hyperinsulinemic- euglycemic-euaminoacidemic clamp (HEAC) procedure would accurately measure the
sensitivity to insulin for its actions on concomitant carbohydrate and protein metabolism in MHD patients.
Methods: We examined 35 MHD patients and 17 control subjects with normal kidney function by
hyperinsulinemic-euglycemic clamp (HEGC) followed by HEAC clamp procedure to obtain leucine disposal rate
(LDR) along with isotope tracer methodology to assess whole body protein turnover.
Results: The glucose disposal rate (GDR) by HEGC was 5.1 ± 2.1 mg/kg/min for the MHD patients compared to
6.3 ± 3.9 mg/kg/min for the controls (p = 0.38). The LDR during HEAC was 0.09 ± 0.03 mg/kg/min for the MHD
patients compared to 0.11 ± 0.05 mg/kg/min for the controls (p = 0.009). The LDR level was correlated with whole
body protein synthesis (r = 0.25; p = 0.08), with whole body protein breakdown (r = −0.38 p = 0.01) and net protein
balance (r = 0.85; p < 0.001) in the overall study population. Correlations remained significant in subgroup analysis.
The GDR derived by HEGC and LDR correlated well in the controls (r = 0.79, p < 0.001), but less so in the MHD
patients (r = 0.58, p < 0.001).
Conclusions: Leucine disposal rate reliably measures amino acid utilization in MHD patients and controls in
response to high dose insulin.
Keywords: Leucine disposal rate, Insulin resistance, Maintenance hemodialysis, Protein energy wasting, Glucose
disposal rate
Background
Protein energy wasting (PEW) is known to exist in a large
number of patients with end stage renal disease (ESRD)
and is associated with increased risk of infections, hospi-
talizations, and death [1–7]. We have previously shown
that type 2 diabetes mellitus (DM), a known insulin resist-
ant state, has been identified as an independent predictor
of loss of lean body mass (LBM) in incident and prevalent
patients receiving maintenance hemodialysis (MHD) [8].
We have also demonstrated that insulin resistance mea-
sured by practical methods such as homeostatic model
assessment (HOMA) is negatively associated with percent
change with arterial plasma leucine concentrations in
response to high dose insulin administration suggesting
insulin mediated AA uptake into muscle or suppression of
protein breakdown or both in MHD patients [9]. As the
major anabolic hormone of the body responsible for not
only carbohydrate metabolism, but also amino acid and* Correspondence: Alp.Ikizler@vanderbilt.edu
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fatty acid metabolism, it is conceivable that impaired insu-
lin signaling could lead to PEW, an entity described by the
loss of LBM [10].
An important aspect of the evaluation of insulin sensi-
tivity in any physiologic or non-physiologic state is the
precision of its estimate. While assessment of carbohy-
drate metabolism has been well studied in multiple
settings, there are limited studies on assessment of insu-
lin’s effects on protein metabolism in vivo, especially in
disease states with known metabolic defects such as
advanced kidney disease. We have previously shown that
in MHD patients, plasma amino acid concentrations
decrease during the hyperinsulinemic-euglycemic clamp
(HEGC) procedure in relation to the glucose disposal
rate (GDR) [9]. While these data indicate a close rela-
tionship between carbohydrate and protein metabolism
in response to a hyperinsulinemic state, there remains
need for examination of amino acid metabolism during
the absorptive state, where the anabolic effects of insulin
are substantially different compared to the post-absorptive
state.
In order to examine this issue further, we performed a
hyperinsulinemic-euglycemic-euaminoacidemic (HEAC)
clamp study with the primary aim of developing a disposal
rate for precise assessment of amino acid metabolism.
Since it is neither synthesized nor degraded in muscle and
its utilization is mainly driven by insulin, we used leucine
as the representative amino acid for these assessments.
Based on our previous data, we also hypothesized that the
sensitivity to insulin for protein metabolism would correl-
ate with similar sensitivity for glucose metabolism in the
MHD patients and controls without kidney disease.
Methods
Study population
A total of 52 subjects, 35 MHD patients from the
Vanderbilt University Outpatient Dialysis Unit and 17
volunteers without kidney disease were recruited between
November 2011 and December 2014. Primary inclusion
criteria for MHD group was being on MHD therapy at
least 6 months with well-functioning hemodialysis vascu-
lar access and, on a thrice-weekly MHD program receiv-
ing an adequate dose of dialysis (single pool Kt/V > 1.2).
Exclusion criteria included patients with active infectious
or inflammatory disease (i.e., vascular access infections,
active connective tissue disorder, active cancer, HIV, and
liver disease) and patients hospitalized within the last
month prior to the study. Patients receiving steroids
(>5 mg/day) and/or immunosuppressive agents and
patients with Type 1 DM and type 2 DM who were using
insulin or insulin-sensitizing medications were also
excluded. The Institutional Review Board of Vanderbilt
University approved the study protocol and written
informed consent was obtained from all study patients.
Study procedures
Hyperinsulinemic-euglycemic (HEGC) clamp protocol
All studies were performed after an overnight 8-h fasting
period at the General Clinical Research Center (GCRC)
at Vanderbilt University Medical Center (VUMC). Clamp
studies were performed on a non-dialysis day in order to
eliminate the potential effects of the hemodialysis therapy.
On the morning of the clamp study, for the MHD
patients, the dialysis shunt was accessed using 15-gauge
fistula needles placed in opposite directions at least 4
fingerbreadths apart. The venous needle was used for
the infusion of insulin and dextrose. Arterial blood
samples were taken through the dialysis needle placed at
the arterial side of the dialysis access. An IV was placed
into the contralateral forearm vein (preferably in a retro-
grade fashion) to obtain samples of venous blood. For
the control subjects, an IV was inserted into an antecu-
bital vein for the infusion of all test substances. Second
and third IVs were placed antegradely and retrogradely
in the opposite arm for blood sampling. The antegrade
IV was placed distal to the retrograde IV and the hand
was kept in a heated box to achieve arterialization of the
venous blood [11]. The remaining IV was used for venous
sampling.
A schematic diagram of the metabolic study protocol
is depicted in Fig. 1. After obtain blood and breath
samples at time point 0, bolus injection of NaH13CO3
(0.12 mg/kg), L-(1-13C) Leucine (7.2 μmol/kg), L-(ring-
2H5) Phenylalanine (3.6 μmol/kg), and 6,6-
2H2 Glucose
(3.6 mg/kg) to prime the CO2, Leucine, Phenylalanine,
and Glucose pools and a continuous infusion of labeled
Leucine (0.12 μmol/kg/min), Phenylalanine (0.06 μmol/
kg/min) and Glucose (0.06 mg/kg/min) started and
continued throughout the remainder of the study. The
initial 2 h were for tracer equilibration. During the
equilibration period, forearm blood flow was estimated
by using capacitance plethysmography (model 2560 with
URI/CP software version 3.0; Moro Bay, CA, USA).
Metabolic cart (Med Graphics CPX/D metabolic cart;
software version 6.1. St. Paul, MN) was used to measure
simultaneous energy expenditure and respiratory quotient.
After equilibration period, baseline blood and breath
sampling obtained between T120 min and T150 min for
every 15 min. A primed infusion of crystalline insulin at
the concentration of 2.0 mu/kg/min was then started at
time point 150 min and maintained throughout the
study procedure to obtain constant hyperinsulinemia.
The goal plasma insulin concentration was 100μU/mL.
The insulin dose used was determined by the required
dose during HEGC study in patients with ESRD to
suppress hepatic gluconeogenesis and allow the meas-
urement of peripheral insulin resistance [12]. Following
initiation of insulin, target plasma glucose levels were
90 ± 5 mg/dL, achieved by adjustment of 20 % dextrose
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infusion. Constant monitoring of plasma glucose con-
centration was performed every 5 min and of leucine
levels every 10 min using rapid bedside high-performance
liquid chromatography (HPLC) methodology. Once steady
state was reached and confirmed for 90 min, GDR or the
metabolizable glucose “M” value (mg/kg/min insulin
mediated glucose disposal rate) was calculated from
samples taken between time points 240 to 270 min. This
served as an index of in vivo insulin sensitivity. For




Once the HEGC was achieved, a continuous infusion of
a balanced amino acid solution (Freeamine III 10 %, B.
Braun Medical, Inc. Irvine, CA) (amino acid concentra-
tions in Freeamine III: leucine, 910 mg; isoleucine,
690 mg; lysine, 730 mg; valine, 660 mg; phenylalanine,
560 mg; threonine, 400 mg; methionine, 530 mg; trypto-
phan 150 mg; alanine, 710 mg; arginine, 950 mg; glycine,
1400 mg; proline, 1120 mg; serine, 590 mg; histidine,
280 mg; cysteine, <16 mg; phosphoric acid NF, 120 mg;
sodium bisulfite, <100 mg) was administered at variable
dose to achieve and maintain the leucine concentration
similar to baseline state, which was calculated as the aver-
age level of time points 120 min, 135 min, and 150 min.
The formula for computing the periodically adjusted
leucine infusion rate for every 10 min is
R ml=hð Þ ¼ Cd‐Ccð Þ  k  6
The individual components of this formula are as
follows: (Cd-Cc) equals the leucine deficit or excess in
μM/L where Cd is the desired plasma leucine concentra-
tion (μM/L). Multiplication by 6 converts the transfusion
time from 10 min to one hour. Cc, is the actual plasma
leucine concentration (μM/L) at any time point.









Total body blood volume is 8 % of body weight. Multi-
plication by 1 minus hematocrit equals to the total plasma
volume of total body. 9.1 mg is the total leucine amount
in 1 mL of Freeamine III solution. Division by 131.17
(molecular weight of leucine) and further multiplication
by 1000 converts the leucine amount from milligram per
liter to micromoles per liter.
When the steady state condition for leucine was
achieved, the leucine infusion rate was assumed to be
equal to the leucine incorporation rate into protein since
endogenous leucine release from protein is assumed
zero under steady state condition. Leucine disposal rate
(LDR) was obtained by the leucine infusion rate (as in
mg/min) during the final 30 min of the 390-min of study
(steady state period for amino acids) and normalized by
body weight (kg).
Body composition
Within one week of each study, participants underwent
dual-energy x-ray absorptiometry (DEXA) offering a
rapid, non-invasive three-compartment evaluation that
quantifies fat mass, LBM, and bone mineral content with
minimal radiation exposure. All DEXA measurements
were completed on a non-dialysis day using a Lunar
Prodigy iDEXA machine v.11.40.004 (software versions
2003 to 2011, General Electric, Madison, WI).
Laboratory analysis
All blood sampling was performed at the GCRC and
analyzed at VUMC central laboratories. After blood
draw was performed, samples were transported on ice
and centrifuged at 3000 rpm for 15 min before being
2.0 mU/kg/min Insulin Infusion 
Variable infusion of Dextrose (20 %) 
      HEGC 
0 min 120 
Variable infusion of AA solution 
240 270 360 390 150 
Baseline 
Primed Constant Infusion of L-(1-13C) Leucine, L- (ring-2H5) Phenylalanine and (2H2) Glucose 
HEACEquilibration 
Fig. 1 HEGC and HEAC study protocol: AA; amino acid, HEGC; hyperinsulinemic-euglycemic clamp, HEAC; hyperinsulinemic-euglycemic-euaminoacidemic
clamp
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kept frozen at −80° Celsius. Plasma fasting glucose
concentrations were analyzed using the glucose oxidase
method (Glucose analyzer 2; Beckman Coulter, Brea,
CA). Biochemistry measurements were analyzed at the
VUMC Pathology Laboratory. High sensitivity C-reactive
protein (hs-CRP) concentrations were measured by
high-sensitivity particle-enhanced turbidimetric UniCel
DxI Immunoassay system (Beckman Coulter).
Plasma amino acid measurements
Plasma arterial amino acid concentrations were deter-
mined by reverse phase HPLC after derivatization with
phenyliosthiocynate. Individual amino acids were also
placed into groups for analysis purposes. These groups
included branched chain amino acids (BCAA = the sum
of leucine, isoleucine, and valine), essential amino acids
(EAA = the sum arginine, histidine, isoleucine, leucine,
lysine, methionine, phenylalanine, threonine, tryptophan,
and valine), total amino acids (TAA = the sum of all
individual amino acids), and nonessential amino acids
(NEAA = the difference between TAA and EAA) [13].
Whole body protein turnover
The steady-state rates of total whole-body leucine Ra
were calculated by dividing the (13C) leucine infusion
rate by the plasma (13C) KIC enrichment [14]. Steady
state conditions for KIC and CO2 enrichments were
achieved as evidenced by slopes within each phase not
significantly different than zero. Breath 13CO2 was deter-
mined by multiplying the total CO2 production rate by
the breath 13CO2 enrichment. The rate of whole body
leucine oxidation was calculated by dividing breath
13CO2 production by 0.8 (correction factor for the reten-
tion of 13CO2 in the bicarbonate pool) [15] and by the
plasma KIC enrichment. The leucine Rd, an estimate of
whole-body protein synthesis, was determined indir-
ectly by subtracting leucine oxidation from total leucine
Rd. Rates of whole-body protein breakdown, amino
acid oxidation, and protein synthesis were calculated
from the endogenous leucine Ra, the leucine oxidation
rate, and the non-oxidative leucine Rd, respectively, as-
suming that 7.8 % of whole-body protein is composed
of leucine [16].
Statistical analysis
Descriptive statistics were expressed as mean ± SD or
median (IQR) for continuous variables and as frequen-
cies and percentage for categorical variables. Univariate
analysis was performed to compare differences between
cases and controls using Pearson’s χ2 test for categorical
variables and Wilcoxon rank-sum test for continuous
variables. Spearman rank correlations were used to esti-
mate the correlation coefficient between LDR and GDR.
Linear mixed-effects models with random intercepts
were fitted separately to estimate the differences in
leucine, phenylalanine, BCAA, EAA, NEAA, and TAA
levels at baseline, HEGC, and HEAC between groups.
Analyses were performed using R, version 3.2.3 (http://
www.r-project.org/). The 5 % significance level (2-sided)
was used.
Results
Characteristics of study population
Our study cohort comprised of 35 MHD and 17 control
subjects. We screened 45 MHD and 22 control subjects.
Of 45 MHD patients, 3 patients excluded due to active
infection, 3 due to prednisone usage, 3 due to hospitali-
zations within last one month and one patient due to
diabetes mellitus requiring insulin therapy. Of 22 control
subjects, 5 of them were excluded due to one subject
had diabetes mellitus requiring insulin therapy and 4
refused consent. Clinical and laboratory characteristics
of the study population are depicted in Table 1. There
were no significant differences for age, gender, and race
between groups (p = 0.25, p = 0.77, p = 0.23, respectively).
Maintenance hemodialysis patients were significantly
more inflamed compared to control subjects [hs-CRP
4.0 (1.8, 10.6) mg/L for MHD vs 0.9 (0.4, 3.1) mg/L for
control, p < 0.001]. For MHD patients, median time on
dialysis was 34 (17, 120) months. Hypertension, DM and
glomerulonephritis were the primary disorders leading
to ESRD (40, 20 and 20 %, respectively), while one of the
MHD patients had ESRD secondary to bilateral nephrec-
tomy following diagnosis of renal cell carcinoma (3 %),
one had due to polycystic kidney disease (3 %) and five
due to unknown etiology (14 %).
Plasma insulin and glucose concentrations
Median baseline arterial plasma concentrations of insulin
were 12 (9, 20) μU/mL for MHD patients and 12 (5, 14)
μU/mL for control subjects. Insulin infusion resulted in
significant elevation of plasma insulin to median values of
100 (48, 153) μU/mL in the MHD group (P < 0.001 versus
baseline) and 133 (114, 145) μU/mL (p < 0.001 versus
baseline) in the control group. The achieved arterial
plasma concentration of insulin was similar in both
groups (p = 0.20). There was no difference regarding
plasma glucose concentrations between MHD subjects
compared to controls [98 ± 17 mg/dL for MHD patients
versus 105 ± 23 mg/dL for control subjects (p = 0.11)].
The glycemic goal of 90 ± 5 mg/dL for both the HEGC
and HEAC was reached in both groups during clamp
periods.
Plasma amino acid concentrations during the HEGC and
HEAC study
Although the MHD group tended to have higher base-
line concentrations of leucine, this difference was not
Denny et al. BMC Nutrition  (2016) 2:31 Page 4 of 13
statistically significant when compared to control
patients [(104 (83, 124) μmol/L for MHD patients versus
92 (89, 107) μmol/L for control subjects (p = 0.26)].
During HEGC period, insulin administration caused a
consistent decline in plasma leucine concentrations in
both groups. In MHD subjects, plasma leucine concen-
tration decreased to 69 (57, 84) μmol/L (p < 0.001)
whereas in control subjects, it decreased to 58 (48, 75)
μmol/L (p < 0.001). During HEAC period, amino acid
infusion led to an increase in plasma leucine concentra-
tion for both groups, which was sustained at baseline
levels during steady state period [105 (87, 127) μmol/L
for MHD patients (p = 0.95) vs 92 (83, 106) μmol/L for
control subjects (p = 0.73)] (Fig. 2).
Although baseline plasma BCAA and NEAA concen-
trations were slightly higher and EAA and TAA concen-
trations were lower in control subjects compared to
MHD patients, these differences were not statistically
significant (p = 0.64 for BCAA, p = 0.07 for EAA, p =
0.56 for NEAA, and p = 0.17 for TAA). The arterial
plasma BCAA, EAA, NEAA, and TAA concentrations
during both HEGC and HEAC periods are depicted in
Fig. 3. All plasma amino acid groups showed significant
decreases during HEGC and subsequently increased
during HEAC (Table 2).
Glucose and leucine disposal rates
The mean GDR derived by HEGC was 5.1 ± 2.1 mg/kg/
min for MHD patients and 6.3 ± 3.9 mg/kg/min for
control subjects (p = 0.38; Table 3). Similarly, the mean
GDR obtained from HEAC was also slightly higher in
control subjects but the difference did not reach statis-
tical significance (6.7 ± 2.1 mg/kg/min for MHD vs 7.9 ±
4.5 mg/kg/min for control, p = 0.35) (Table 3). The ad-
ministration of amino acid infusion resulted in signifi-
cant increases in GDR both for MHD patients and
control subjects. (P < 0.001) (Fig. 4).
The mean LDR level was statistically significantly
higher in control subjects compared MHD patients
[(0.09 ± 0.03 mg/kg/min for MHD vs 0.11 ± 0.05 mg/kg/
min for control, P = 0.009)] (Table 3).
Correlation coefficients of the GDR derived by HEGC
and LDR are depicted in Fig. 5. There was a significant
positive correlation between GDR and LDR levels for
the whole study population (r = 0.65, p < 0.001, Fig. 5a).
Correlation analysis for the two individual groups
revealed that GDR derived by HEGC and LDR corre-
lated well in the control patients (r = 0.79, p < 0.001,
Fig. 5c), whereas correlation was slightly attenuated in
MHD patients (r = 0.58, p < 0.001, Fig. 5b).
Correlation analysis between leucine disposal rate
derived by HEAC and protein turnover kinetics
The mean ± SD whole body (WB) protein synthesis and
breakdown were 4.8 ± 1.3, 3.1 ± 1.3 mg/kg. fat free mass/
min for MHD patients, 4.7 ± 0.9, 2.7 ± 0.6 mg/kg.fat free
mass/min for control patients. Although WB protein
breakdown rate was numerically higher in MHD patients,
the difference was not statistically significant (p = 0.29).
There was no statistically significant difference for WB
protein synthesis (p = 0.74). The median (IQR) WB pro-
tein net balance rates were 1.5 (1.3, 1.9) mg/kg.fat free
mass/min for MHD and 1.9 (1.4, 2.1) mg/kg. fat free
mass/min for control patients (p = 0.08). There was a near
significant positive correlation between LDR and WB pro-
tein synthesis (r = 0.25; p = 0.08), and significant positive
correlation with WB protein net balance (r = 0.85; p <
0.001) in the overall study population (Fig. 6). Positive







Age,b y 49 ± 15 45 ± 11 0.25
Race, n (%)
African American 28 (80) 11 (65)
Caucasian 7 (20) 6 (35) 0.23
Male sex, n (%) 28 (80) 13 (76) 0.77
Primary Disorder of ESRD, n (%)
Hypertension 14 (40)
Diabetes Mellitus 7 (20)
Glomerulonephritis 7 (20)
RCC Bilateral Nephrectomy 1 (3) – NA
Polycystic Kidney Disease 1 (3)
Other 5 (14)
Dialysis Vintage,c months 34 (17, 120) NA
Body Composition
BMI,b kg/m2 29 ± 6 28 ± 7 0.34
Truncal Fat,b % 38 ± 13 33 ± 12 0.09
Fat Mass,c kg 30 (23, 37) 24 (15, 31) 0.21
Lean Mass,c kg 52 (49, 61) 59 (47, 66) 0.34
BUN,b mg/dL 45 ± 16 13 ± 3 <0.001
Creatinine,b mg/dL 9.7 ± 2.9 0.9 ± 0.1 <0.001
Albumin,b g/dL 3.9 ± 0.4 4.0 ± 0.2 0.34
hs-CRP,c mg/L 4.0 (1.8, 10.6) 0.9 (0.4, 3.1) <0.001
Hematocrit,b % 37 ± 5 43 ± 3 <0.001
Fasting Glucose,b mg/dL 98 ± 17 105 ± 23 0.11
Baseline Insulin,c μU/mL 12.6 (10.7, 19.8) 10.4 (5.2, 13.3) 0.05
HbA1c,b % 5.2 ± 0.6 5.3 ± 0.5 0.33
HOMA-IR,c 2.9 (2.2, 4.4) 2.7 (1.1, 3.5) 0.17
aBUN blood urea nitrogen, ESRD end stage renal disease, HbA1c hemoglobin
A1c, hs-CRP high-sensitivity C-reactive protein, HOMA-IR homeostatic model
assessment of insulin resistance, RCC renal cell carcinoma
bMean ± SD
cMedian (IQR)
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correlations for WB protein synthesis remained signifi-
cant in control group whereas attenuated in MHD pa-
tients [r = 0.10; p = 0.59 for MHD, r = 0.66; p = 0.005
for controls]. Both correlations were significant for
WB protein net balance in subgroups analysis [r = 0.79;
p < 0.001 for MHD, r = 0.94; p < 0.001 for control sub-
jects]. There was a statistically significant negative correl-
ation between LDR and WB protein breakdown (r = −0.38,
p = 0.01). In subgroup analysis, significant negative correl-
ation remained for MHD patients (r = −0.41, p = 0.02),
whereas, no significant correlation observed in control sub-
jects (r = −0.23, p = 0.38).
Sensitivity analysis
We examined the primary outcomes with exclusion of 8
patients in MHD group who had DM. The results
indicated that GDR derived by HEGC levels were
slightly lower in MHD patients compared to controls
(5.5 ± 2.1 mg/kg/min for MHD vs 6.3 ± 3.9 mg/kg/min
for control, p = 0.59). Similarly, no significant difference
was observed for GDR derived by HEAC (6.8 ± 2.1 mg/
kg/min for MHD vs 7.9 ± 4.5 mg/kg/min for control, p
= 0.43). The mean LDR values were 0.09 ± 0.03 mg/kg/
min for MHD and 0.11 ± 0.04 mg/kg/min for controls
(p = 0.03). The correlation analyses were similar to over-
all results. Specifically, there was a significant positive
correlation between GDR and LDR levels in the whole
study population (r = 0.64, p < 0.001), controls (r = 0.78,
p = 0.001) and slightly attenuated in MHD patients (r =
0.52, p = 0.006). The correlation analysis between LDR
derived by HEAC and WB protein turnover kinetics
revealed similar results. There was a positive correlation
between LDR derived by HEAC and WB protein synthe-
sis (r = 0.22, p = 0.14), significant negative correlation
with WB protein breakdown (r = −0.43, p = 0.005) and
significant positive correlation with WB net protein
balance (r = 0.84, p < 0.001) in all study population. Posi-
tive correlation with WB protein synthesis remained
significant (r = 0.66, p = 0.004) for controls and attenu-
ated for MHD patients (r = 0.04, p = 0.84). The negative
correlation with WB protein breakdown remained
significant in MHD patients (r = −0.56, p = 0.004)
whereas no significant correlation found for the control
subjects (r = −0.23, p = 0.37). The significant positive
correlations with WB protein net balance remained
significant in subgroup analysis [r = 0.77, p < 0.001, for
MHD patients and r = 0.94 p < 0.001 for control subjects].
Discussion
Insulin is an important key regulatory hormone with
multiple effects on glucose, protein, and lipid metabolism.




























Fig. 2 Plasma Leucine Concentrations throughout the Clamp Study: Plasma leucine concentration was measured in the basal state and every ten
minutes throughout the HEGC and HEAC studies. Leucine concentrations significantly decreased (p < 0.001) during the HEGC and significantly
increased and maintained at the baseline level during HEAC (p = 0.95 for MHD, p = 0.73 for control subjects)



































































































































Fig. 3 (See legend on next page.)
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in insulin sensitivity on carbohydrate metabolism in ESRD
patients on MHD. In the present study, we aimed to
examine insulin sensitivity in terms of protein metabolism
using a precise measure for amino acid utilization. Our
data suggested that there is a statistically significant
difference in amino acid utilization between MHD
patients and matched controls. Interestingly, we were not
able to confirm the previously published data, which
reported a statistically significant difference in carbohy-
drate metabolism between MHD patients and controls.
The correlation analyses with whole body protein synthe-
sis, breakdown and net balance confirmed that we were
able to accurately measure amino acid disposal rates both
in MHD patients and controls without kidney disease.
Presence or absence of diabetes did not influence the
results indicating that this approach can be used in
multiple settings. Finally, we observed that GDR and LDR
correlated well in the control subjects, but less in MHD
patients suggesting that insulin signaling might be coordi-
nated differently at the protein level as compared to
carbohydrate metabolism in ESRD patients on MHD.
The primary aim of our study was to develop and test
the dual clamp procedure in MHD patients and individ-
uals without kidney disease. Several technical aspects of
our study indicate that this methodology can be applied
in multiple settings. First, euglycemia and euaminoacide-
mia (based on plasma glucose and leucine concentra-
tions) were achieved successfully at both time points in
both groups. Second, we were able to achieve targeted
insulin levels during glucose and amino acid clamps in
both groups. The potential bias that could arise due to
lack of agreement in these values is obvious and similar-
ity is necessary in completing the clamp study. Achieve-
ment of target insulin concentrations will also suppress
leucine production from protein degradation, which is
critical for the reliability of the LDR. Third, leucine was
chosen as the amino acid to be measured based on
results from our previous study demonstrating correl-
ation of leucine levels with differences seen in insulin
resistance [9]. Measurement of leucine was achievable at
the bedside using rapid HPLC, thus allowing for adjust-
ment of the amino acid solution appropriately during
the study period. Fourth, we were able to demonstrate a
range of LDR in both MHD patients and individuals
without kidney disease suggesting biological plausibility.
Furthermore, the significant correlation of LDR with
whole body protein kinetics particularly with protein
synthesis, suggests that the LDR is reliable, relatively
easy to perform at bedside and physiologically relevant
measure of protein metabolism without further examin-
ation of protein turnover kinetics, the commonly used
methodology for this purpose.
There are also several observations during the study
that require further explanation. Our results showed that
GDR values significantly increased during HEAC period
as compared to HEGC period. Picchini et al. previously
demonstrated that glucose uptake does increase when
the HEGC is extended beyond the customary 2-h study
period and the time difference between the HEGC and
the HEAC can be at times close to 4 h suggesting a
possible explanation for the observed increase between
clamp periods [17]. There are also studies that show that
leucine infusion per se can increase glucose utilization
in healthy individuals [18, 19]. Overall, the underlying
cause of this increase in GDR might be due to either
factors combined or one alone. The fact that both
patient groups increased their GDR equally suggests that
this observation is unlikely to be related to or worsened
by advanced kidney disease. One could suggest that the
separation of the GDR obtained during the HEGC from
the LDR obtained during the HEAC introduces bias as
these time points represent different states of insulin
sensitivity. From an analytical perspective, we chose to
use GDR derived from HEGC for analysis instead of
(See figure on previous page.)
Fig. 3 Plasma BCAA, EAA, NEAA, and TAA Levels during the HEGC and HEAC: Within group testing revealed achievement of statistical significance
for change in levels between the three time points in all groups (Table 2). Testing between groups at baseline revealed no statistically significant
differences (p = 0.64 for BCAA, p = 0.07 for EAA, p = 0.56 for NEAA, p = 0.17 for TAA). BCAA; branched chain amino acid, EAA; essential amino acid,
NEAA; nonessential amino acid; TAA, total amino acid
Table 2 Arterial concentrations of branched chain, essential, nonessential, and total amino acids during hyperinsulinemic statesa
Hemodialysis Control
Amino Acids Baseline HEGC HEAC P Baseline HEGC HEAC P
BCAA 295 (240, 346) 199 (157, 237) 298 (267, 347) <0.001 314 (253, 342) 203 (159, 226) 344 (298, 378) <0.001
EAA 779 (615, 1230) 597 (445, 998) 929 (737, 1243) <0.001 701 (590, 769) 522 (426, 583) 622 (582, 822) <0.001
NEAA 1234 (1030, 1458) 1049 (930, 1230) 1355 (1209, 1710) <0.001 1340 (1049, 1622) 1083 (757, 1246) 1485 (1331, 1764) <0.001
TAA 2243 (1883, 2503) 1721 (1140, 2104) 2448 (1969, 2733) <0.001 2070 (1889, 2316) 1635 (1362, 1854) 1926 (1551, 2293) <0.001
BCAA branched chain amino acid, EAA essential amino acid, HEAC hyperinsulinemic-euglycemic-euaminoacidemic clamp, HEGC hyperinsulinemic-euglycemic
clamp, NEAA nonessential amino acid, TAA total amino acid
aAll amino acids expressed as median (IQR), μmol/L. P values were derived from linear mixed-effects models with random intercepts
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GDR obtained from HEAC, since GDR at HEGC repre-
sents a real fasting state of amino acid feeding.
The current study did not reveal a significant differ-
ence between the GDR of the controls and the MHD
subjects, somewhat contrary to published data. It is
conceivable that the current lack of significance in abso-
lute difference between the two groups is due only to
the sample size of this study although we are reporting
the largest study of its kind in MHD patients. It is also
possible that this difference is the result of the individ-
uals selected for study. In looking at the MHD subjects
studied, one can see that this cohort of individuals is
relatively healthy compared to the general population
currently receiving renal replacement therapy as exem-
plified by serum albumin concentrations comparable to







HEGC GDR, mg/kg/min 5.1 ± 2.1 6.3 ± 3.9 0.38
HEAC GDR, mg/kg/min 6.7 ± 2.1 7.9 ± 4.5 0.35
Protein Metabolism
Leucine Disposal Rate, mg/kg/min 0.09 ± 0.03 0.11 ± 0.05 0.009
GDR glucose disposal rate, HEAC hyperinsulinemic-euglycemic-
euaminoacidemic clamp, HEGC hyperinsulinemic-euglycemic clamp



















Fig. 4 Glucose disposal rate in each group at HEGC and HEAC: Difference in GDR between the two time points in both the MHD subjects and
controls achieved statistical significance (P < 0.001 in each)









LDR by HEAC (mg/kg/min)







































LDR by HEAC (mg/kg/min)







































LDR by HEAC (mg/kg/min)
CONTROL

































Fig. 5 Spearman Correlation Analysis of Glucose Disposal and Leucine Disposal Rates: a All patients, b Hemodialysis patients, c Control Patients:
HEGC; hyperinsulinemic euglycemic clamp
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the controls studied. This is also one of the few studies
where MHD patients are studied with appropriate
controls, especially ones that have similar demographic
and nutritional characteristics such as age, race, gender
and body mass index. This may suggest that the differ-
ence between the two appropriately matched popula-
tions is not quite as large for GDR as previously
suggested and is consistent with a recently published
study in CKD patients not yet on maintenance dialysis
[20]. Implementation of suitable control groups in future
studies would provide valuable insight to this question.
Interestingly enough, we were able to detect a statisti-
cally significant difference between MHD patients and
controls for LDR. The clinical and research implications
of this observation are several folds, especially in the
light of the aforementioned lack of difference in GDR.
First and foremost important implication is that a signifi-
cant number of MHD patients might be missing a poten-
tial opportunity for improvement if their management of
insulin metabolism is solely based on markers of glucose
metabolism such as random glucose concentrations or
HbA1c. Indeed, it is generally believed that diabetes is
somewhat resolved once MHD is commenced and anti-
diabetic agents are sparingly used in ESRD patients. These
data further suggest that the choice of anti-diabetic agents
in ESRD should be preferentially ones that improve insu-
lin sensitivity rather than simply lowering blood glucose
concentrations. Finally, it is imperative that further research
examining anti-diabetic strategies in MHD patients must
incorporate markers of protein metabolism in addition to
other outcomes.
An intriguing finding in this study was that the correl-
ation between GDR and LDR was relatively strong for
the overall cohort; however, when compared within
groups, the correlation coefficient was attenuated in
MHD patients compared to controls (Fig. 5b and c). This
observation suggests that the metabolic response of carbo-
hydrates and amino acids to insulin is coordinated differ-
entially in the setting of advanced kidney disease, which is
in line with the data showing the discrepancy between
GDR and LDR when comparing MHD patients and
matched controls. In animal studies, Mitch and colleagues
have shown that kidney disease leads to decrease insulin
receptor substrate 1 (IRS-1) with a compensatory increase
Fig. 6 Correlation Analysis Between Whole Body Protein Synthesis and Net Balance with LDR derived by HEAC: HEAC; hyperinsulinemic
euaglycemic-euaminoacidemic clamp, All correlation analysis performed with spearman correlation coefficient
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in IRS-2 [21] and reduced Akt phosphorylation. This
finding might support the discrepancy in insulin sensitiv-
ity on carbohydrate and protein metabolism in our study,
although further examination at the muscle tissue level
would provide the more insight to this novel in vivo obser-
vation in the setting of advanced kidney disease.
There are several strengths in this study. This is the
first study to develop and test a physiologically relevant
method for assessing insulin sensitivity for protein
metabolism in humans. It is one of the largest cohorts
using a dual-clamp method in MHD patients and individ-
uals without kidney disease. The inclusion of a control
population that represents the clinical and demographic
characteristics of the contemporary ESRD patient popula-
tion is a unique strength. The inclusion of metabolic-
studies with labeled isotopes further strengthens the study
and the validity of the results obtained. There are also sev-
eral limitations in this study. Predominance of male gen-
der and African-American race limits the generalizability
of the study. It is possible that statistical significance
would be achieved when comparing GDR between groups
with a larger sample size; however, the current findings
may be true in that the previously perceived difference
between the two groups may not be as large as once
thought as recently has been shown in two separate stud-
ies in CKD patients. The methodology is complex and
cannot be readily applied in every setting. Nevertheless, it
is arguably the most appropriate research approach for
measuring insulin action in the stimulated setting. Further
studies exploring more practical measures that relate to
amino acid disposal are necessary to further advance
knowledge in this area. Finally, LDR does not necessarily
provide direct evidence of the effects of insulin on differ-
ent components of protein metabolism, namely protein
synthesis and breakdown. Additional studies incorporating
stable isotope technique at different settings of amino acid
concentrations would shed further light into those aspects
of protein homeostasis, both in healthy controls and
chronic disease settings such as ESRD.
Conclusion
LDR derived by HEAC technique offers a reliable and
physiological method to quantify insulin sensitivity on
protein turnover in MHD patients and individuals
without kidney disease. There is a statistically significant
difference between MHD patients and controls for LDR,
but not for GDR. The additional data showing attenuated
correlation between GDR and LDR in response to insulin
suggest that the mechanisms contributing to the resist-
ance in protein metabolism extend beyond carbohydrate
metabolism in the MHD patients. These findings require
further investigation for understanding the effects of
insulin signaling on protein metabolism in MHD patients.
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